September 8, 2017

Translational Research Program Grants

By msequeira

Leukemia & Lymphoma Society, Inc.


To accelerate clinical applications of laboratory findings relevant to improved diagnosis and management of leukemia, lymphoma, myeloma and other hematopoietic malignancies. Proposals of particular interest will address:
1. Personalized medicine approach for cancer treatment.
2. Development of novel therapies and/or novel therapeutic strategies including those that target mutational and epigenetic events within the microenvironment.
3. Improvements of safety and efficacy of stem cell transplantation.
4. Long-term outcome assessment following therapies.
5. Progress in understanding neoplastic stem cell growth and differentiation as well as cancer cell/microenivronmental interactions especially with translation to novel therapies.
6. The advancement of therapies in pediatric indications with novel approaches or to minimize therapy-related effects of existing treatments.

Who Can Apply:

The society welcomes applications from both US citizens and noncitizens who hold a PhD, MD, DVM or equivalent degree and have been appointed not-for-profit institution at the time the funding commences.


Up to $200,000 (including direct costs and a maximum overhead of $19,982) per year for three years.


Sep. 29, 2017 (letters of intent); Nov. 15, 2017 (full application)

Grant Period:

May 2018 (award notification); July 1, 2018 (award begins)


For more information visit

Tags: Funding, Funding Opps, Research